Tag: hormoneReplacementTherapy

Articles

• Birth control pill use and breast cancer
• Breast density and breast cancer risk and recurrence
• Hormone replacement therapy (HRT) and breast cancer
• Latinas less likely to develop BC but outcomes are less favorable
• Lobular breast cancer and LCIS characteristics

News

10/10/15

Weight gain, alcohol use, low physical activity & HRT linked to BC

09/29/13

Women with lower estrogen levels have higher HRT-related BC risk

11/06/11

Combination HRT doubles BC risk among women with breast tenderness

05/10/11

Apigenin may prevent BC that develops in response to progestin

07/29/10

HRT increases risk of BC, especially for those with dense breasts

02/22/10

Benign breast disease less likely to progress if having children young

Studies

• Post cancer care in women with an increased risk of malignancy or previous malignancy: the use of hormone replacement therapy and alternative treatments. Cite
  Sassarini J, Lumsden MA. Post cancer care in women with an increased risk of malignancy or previous malignancy: the use of hormone replacement therapy and alternative treatments.. Best Practice & Research Clinical Endocrinology & Metabolism. Elsevier BV; 2023;:101854 10.1016/j.beem.2023.101854
• THU477 Drivers Of Estrogen Induced Invasive Lobular Carcinoma Cite
  Ufondu C, Clem L, Musick M, Sikora MJ, Ostrander JH. THU477 Drivers Of Estrogen Induced Invasive Lobular Carcinoma. Journal of the Endocrine Society. The Endocrine Society; 2023; 7 10.1210/jendso/bvad114.2105
• Long-term breast cancer incidence trends by mammography, obesity, and menopausal hormone therapy Cite
  Chlebowski RT, Aragaki AK. Long-term breast cancer incidence trends by mammography, obesity, and menopausal hormone therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07113-9
• Menopausal hormone therapy and dementia: nationwide, nested case-control study Cite
  Pourhadi N, Mørch LS, Holm EA, Torp-Pedersen C, Meaidi A. Menopausal hormone therapy and dementia: nationwide, nested case-control study. BMJ. BMJ; 2023;:e072770 10.1136/bmj-2022-072770
• Hysterectomy, bilateral oophorectomy, and breast cancer risk in a racially diverse prospective cohort study Cite
  Lovett SM, Sandler DP, O’Brien KM. Hysterectomy, bilateral oophorectomy, and breast cancer risk in a racially diverse prospective cohort study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2023; 10.1093/jnci/djad038
• Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk Cite
  Sund M, Garmo H, Andersson A, Margolin S, Ahlgren J, Valachis A. Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-06871-w
• Associations of breast cancer related exposures and gene expression profiles in normal breast tissue—The Norwegian Women and Cancer normal breast tissue study Cite
  Krum‐Hansen S, Standahl Olsen K, Anderssen E, Frantzen JO, Lund E, Paulssen RH. Associations of breast cancer related exposures and gene expression profiles in normal breast tissue—The Norwegian Women and Cancer normal breast tissue study. Cancer Reports. Wiley; 2023; 10.1002/cnr2.1777
• Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study Cite
  Cold S, Cold F, Jensen M, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2022; 10.1093/jnci/djac112
• Associations of coffee/caffeine consumption with postmenopausal breast cancer risk and their interactions with postmenopausal hormone use Cite
  Yaghjyan L, McLaughlin E, Lehman A, Neuhouser ML, Rohan T, Lane DS, et al. Associations of coffee/caffeine consumption with postmenopausal breast cancer risk and their interactions with postmenopausal hormone use. European Journal of Nutrition. Springer Science and Business Media LLC; 2022; 10.1007/s00394-022-02899-8
• Association Between Lifestyle Changes, Mammographic Breast Density, and Breast Cancer Cite
  Lester SP, Kaur AS, Vegunta S. Association Between Lifestyle Changes, Mammographic Breast Density, and Breast Cancer. The Oncologist. Oxford University Press (OUP); 2022; 10.1093/oncolo/oyac084
• Association between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and death due to COVID-19: a cohort study Cite
  Sund M, Fonseca-Rodríguez O, Josefsson A, Welen K, Fors Connolly A. Association between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and death due to COVID-19: a cohort study. BMJ Open. BMJ; 2022; 12:e053032 10.1136/bmjopen-2021-053032
• Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. Cite
  Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJ, Andrieu N, et al. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.. Apollo - University of Cambridge Repository; 2022; 10.17863/CAM.80147
• Updated fraction of cancer attributable to lifestyle and environmental factors in Denmark in 2018 Cite
  Tybjerg AJ, Friis S, Brown K, Nilbert MC, Morch L, Køster B. Updated fraction of cancer attributable to lifestyle and environmental factors in Denmark in 2018. Scientific Reports. Springer Science and Business Media LLC; 2022; 12 10.1038/s41598-021-04564-2
• Hormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study Cite
  Rosenberg V, Bareket-Samish A, Chodick G, Siegelmann-Danieli N. Hormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study. International Journal of Women's Health. Informa UK Limited; 2021; Volume 13:1207-1216 10.2147/ijwh.s311696
• Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis Cite
  Poggio F, Del Mastro L, Bruzzone M, Ceppi M, Razeti MG, Fregatti P, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06436-9
• An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites Cite
  Papadimitriou N, Markozannes G, Kanellopoulou A, Critselis E, Alhardan S, Karafousia V, et al. An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites. Nature Communications. Springer Science and Business Media LLC; 2021; 12 10.1038/s41467-021-24861-8
• Breast cancer incidence and mortality in relation to hormone replacement therapy use among postmenopausal women: results from a prospective cohort study Cite
  Jiang Y, Xie Q, Chen R. Breast cancer incidence and mortality in relation to hormone replacement therapy use among postmenopausal women: results from a prospective cohort study. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.06.010
• Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden Cite
  Johansson A, Christakou AE, Iftimi A, Eriksson M, Tapia J, Skoog L, et al. Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. JAMA Network Open. American Medical Association (AMA); 2021; 4:e2114716 10.1001/jamanetworkopen.2021.14716
• Can breast cancer be stopped? Modifiable risk factors of breast cancer among women with a prior benign or premalignant lesion Cite
  Lilleborge M, Falk RS, Sørlie T, Ursin G, Hofvind S. Can breast cancer be stopped? Modifiable risk factors of breast cancer among women with a prior benign or premalignant lesion. International Journal of Cancer. Wiley; 2021; 10.1002/ijc.33680
• Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 1.5 million women over age 65: a retrospective observational study Cite
  Baik S, McDonald C. Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 1.5 million women over age 65: a retrospective observational study. Authorea, Inc.; 2021; 10.22541/au.161873076.60547427/v1
• Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy Cite
  Michaelson-Cohen R, Gabizon–Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, et al. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. European Journal of Cancer. Elsevier BV; 2021; 148:95-102 10.1016/j.ejca.2021.02.007
• Long-term weight change and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study Cite
  Ellingjord-Dale M, Christakoudi S, Weiderpass E, Panico S, Dossus L, Olsen A, et al. Long-term weight change and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. International Journal of Epidemiology. Oxford University Press (OUP); 2021; 10.1093/ije/dyab032
• Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50–59 Years of Age Cite
  Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, et al. Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50–59 Years of Age. American Journal of Epidemiology. Oxford University Press (OUP); 2020; 190:365-375 10.1093/aje/kwaa210
• Abstract PS7-05: Estrogen-based hormone replacement therapy [E-HRT] reduces all-cause, breast cancer, and Alzheimer's dementia mortality Cite
  Ragaz J, Shakeraneh S, Qian H, Wong H, Spinelli JJ, Wilson KS. Abstract PS7-05: Estrogen-based hormone replacement therapy [E-HRT] reduces all-cause, breast cancer, and Alzheimer's dementia mortality. Poster Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-ps7-05
• Breast cancer risk factors by mode of detection among screened women in the Cancer Prevention Study-II Cite
  Gaudet MM, Deubler E, Diver WR, Puvanesarajah S, Patel AV, Gansler T, et al. Breast cancer risk factors by mode of detection among screened women in the Cancer Prevention Study-II. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-020-06025-2
• Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases Cite
  Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. BMJ; 2020;:m3873 10.1136/bmj.m3873
• Genetically predicted C-reactive protein associated with breast cancer risk: interrelation with estrogen and cancer molecular subtypes using a Mendelian randomization Cite
  Jung SY, Papp JC, Sobel EM, Pellegrini M, Yu H, Zhang Z. Genetically predicted C-reactive protein associated with breast cancer risk: interrelation with estrogen and cancer molecular subtypes using a Mendelian randomization. Research Square; 2020; 10.21203/rs.3.rs-57683/v1
• Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials Cite
  Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA. American Medical Association (AMA); 2020; 324:369 10.1001/jama.2020.9482
• Hormone replacement therapy and mammographic density: a systematic literature review Cite
  Azam S, Jacobsen KK, Aro AR, Lynge E, Andersen ZJ. Hormone replacement therapy and mammographic density: a systematic literature review. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 182:555-579 10.1007/s10549-020-05744-w
• Menopausal hormone therapy use and long‐term all‐cause and cause‐specific mortality in the Long Island Breast Cancer Study Project Cite
  Wang T, Bradshaw PT, Moorman PG, Nyante SJ, Nichols HB, Shantakumar S, et al. Menopausal hormone therapy use and long‐term all‐cause and cause‐specific mortality in the Long Island Breast Cancer Study Project. International Journal of Cancer. Wiley; 2020; 147:3404-3415 10.1002/ijc.33174
• Hormone Replacement Therapy, Breast Cancer Risk Factors, and Breast Cancer Risk: A Nationwide Population-Based Cohort Cite
  Yoo T, Han KD, Kim D, Ahn J, Park W, Chae BJ. Hormone Replacement Therapy, Breast Cancer Risk Factors, and Breast Cancer Risk: A Nationwide Population-Based Cohort. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2020; 29:1341-1347 10.1158/1055-9965.epi-20-0038
• Incidence and Risk Factors of Ovarian Cancer and Breast Cancer Following Prophylactic Surgery: A Retrospective Cohort Study Cite
  Rettenmaier MA, Micha JP, Bohart R, Epstein HD, King MM, Goldstein BH. Incidence and Risk Factors of Ovarian Cancer and Breast Cancer Following Prophylactic Surgery: A Retrospective Cohort Study. Journal of Gynecologic Surgery. Mary Ann Liebert Inc; 2020; 36:189-193 10.1089/gyn.2019.0135
• Forty‐year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women Cite
  Chlebowski RT, Aragaki AK, Anderson GL, Prentice RL. Forty‐year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women. Cancer. Wiley; 2020; 126:2956-2964 10.1002/cncr.32846
• Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study Cite
  Glaser RL, York AE, Dimitrakakis C. Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. BMC Cancer. Springer Science and Business Media LLC; 2019; 19 10.1186/s12885-019-6457-8
• Abstract GS5-00: Long-term influence of estrogen plus progestin and estrogen alone use on breast cancer incidence: The Women's Health Initiative randomized trials Cite
  Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick M, Pan K, et al. Abstract GS5-00: Long-term influence of estrogen plus progestin and estrogen alone use on breast cancer incidence: The Women's Health Initiative randomized trials. General Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-gs5-00
• Mammographic Density and Screening Sensitivity, Breast Cancer Incidence and Associated Risk Factors in Danish Breast Cancer Screening Cite
  Lynge E, Vejborg I, Andersen Z, von Euler-Chelpin M, Napolitano G. Mammographic Density and Screening Sensitivity, Breast Cancer Incidence and Associated Risk Factors in Danish Breast Cancer Screening. Journal of Clinical Medicine. MDPI AG; 2019; 8:2021 10.3390/jcm8112021
• Menopausal hormone therapy and 20-year breast cancer mortality Cite
  Beral V, Peto R, Pirie K, Reeves G. Menopausal hormone therapy and 20-year breast cancer mortality. The Lancet. Elsevier BV; 2019; 394:1139 10.1016/s0140-6736(19)32033-1
• Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence Cite
  Collaborative Group on Hormonal Factors in Breast Cancer . Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet. Elsevier BV; 2019; 394:1159-1168 10.1016/s0140-6736(19)31709-x
• The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study Cite
  Arriaga ME, Vajdic CM, Canfell K, MacInnis RJ, Banks E, Byles JE, et al. The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study. International Journal of Cancer. Wiley; 2019; 145:2383-2394 10.1002/ijc.32231
• Abstract P6-13-06: Estrogen-based hormone replacement [HRT] therapy is substantially more effective than tamoxifen in reducing breast cancer mortality and breast cancer case fatality ratio: Emergence of a new paradigm Cite
  Ragaz J, Shakeraneh S, Qian H, Wilson K, Wong H, Spinelli J. Abstract P6-13-06: Estrogen-based hormone replacement [HRT] therapy is substantially more effective than tamoxifen in reducing breast cancer mortality and breast cancer case fatality ratio: Emergence of a new paradigm. Poster Session Abstracts. American Association for Cancer Research; 2019; 10.1158/1538-7445.sabcs18-p6-13-06
• Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer Cite
  Wunderle M, Pretscher J, Brucker SY, Volz B, Hartmann A, Fiessler C, et al. Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 174:453-461 10.1007/s10549-018-05115-6
• The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women’s characteristics: is it the same? Cite
  Théberge I, Vandal N, Guertin M, Perron L. The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women’s characteristics: is it the same?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 174:525-535 10.1007/s10549-018-05095-7
• Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study Cite
  Salagame U, Banks E, O’Connell DL, Egger S, Canfell K. Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study. PLOS ONE. Public Library of Science (PLoS); 2018; 13:e0205034 10.1371/journal.pone.0205034
• Number of Risky Lifestyle Behaviors and Breast Cancer Risk Cite
  Ellingjord-Dale M, Vos L, Vik Hjerkind K, Hjartåker A, Russnes HG, Tretli S, et al. Number of Risky Lifestyle Behaviors and Breast Cancer Risk. JNCI Cancer Spectrum. Oxford University Press (OUP); 2018; 2 10.1093/jncics/pky030
• Interactions of alcohol and postmenopausal hormone use in regards to mammographic breast density Cite
  Yaghjyan L, Colditz G, Eliassen H, Rosner B, Gasparova A, Tamimi RM. Interactions of alcohol and postmenopausal hormone use in regards to mammographic breast density. Cancer Causes & Control. Springer Science and Business Media LLC; 2018; 29:751-758 10.1007/s10552-018-1053-9
• Different menopausal hormone regimens and risk of breast cancer Cite
  Brusselaers N, Tamimi R, Konings P, Rosner B, Adami H, Lagergren J. Different menopausal hormone regimens and risk of breast cancer. Annals of Oncology. Elsevier BV; 2018; 29:1771-1776 10.1093/annonc/mdy212
• Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study Cite
  Nattenmüller CJ, Kriegsmann M, Sookthai D, Fortner RT, Steffen A, Walter B, et al. Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4548-6
• Nonsteroidal anti‐inflammatory drug use and breast cancer risk in a European prospective cohort study Cite
  Cairat M, Fournier A, Murphy N, Biessy C, Scalbert A, Rinaldi S, et al. Nonsteroidal anti‐inflammatory drug use and breast cancer risk in a European prospective cohort study. International Journal of Cancer. Wiley; 2018; 143:1688-1695 10.1002/ijc.31570
• Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies Cite
  Kim S, Ko Y, Lee HJ, Lim J. Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 170:667-675 10.1007/s10549-018-4782-2
• Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers Cite
  Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncology. American Medical Association (AMA); 2018; 4:1059 10.1001/jamaoncol.2018.0211
• Interactions of coffee consumption and postmenopausal hormone use in relation to breast cancer risk in UK Biobank Cite
  Yaghjyan L, Rich S, Mao L, Mai V, Egan KM. Interactions of coffee consumption and postmenopausal hormone use in relation to breast cancer risk in UK Biobank. Cancer Causes & Control. Springer Science and Business Media LLC; 2018; 29:519-525 10.1007/s10552-018-1028-x
• Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics Cite
  Rice MS, Tamimi RM, Bertrand KA, Scott CG, Jensen MR, Norman AD, et al. Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 170:129-141 10.1007/s10549-018-4735-9
• Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study Cite
  Busund M, Bugge NS, Braaten T, Waaseth M, Rylander C, Lund E. Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study. International Journal of Cancer. Wiley; 2018; 142:2293-2302 10.1002/ijc.31266
• Abstract 4255: Associations of coffee consumption and caffeine intake with mammographic breast density Cite
  Yaghjyan L, Colditz G, Rosner B, Gasparova A, Tamimi R. Abstract 4255: Associations of coffee consumption and caffeine intake with mammographic breast density. Epidemiology. American Association for Cancer Research; 2017; 10.1158/1538-7445.am2017-4255
• Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women Cite
  Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women. JAMA. American Medical Association (AMA); 2017; 318:2224 10.1001/jama.2017.18261
• Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study Cite
  Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, et al. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2017; 186:1329-1340 10.1093/aje/kwx206
• Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History Cite
  Grandi G, Toss A, Cagnacci A, Marcheselli L, Pavesi S, Facchinetti F, et al. Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History. Clinical Breast Cancer. Elsevier BV; 2018; 18:e15-e24 10.1016/j.clbc.2017.10.016
• Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy Cite
  Fagerholm R, Faltinova M, Aaltonen K, Aittomäki K, Heikkilä P, Halttunen-Nieminen M, et al. Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy. Familial Cancer. Springer Science and Business Media LLC; 2017; 17:321-331 10.1007/s10689-017-0046-2
• Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality Cite
  Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality. JAMA. American Medical Association (AMA); 2017; 318:927 10.1001/jama.2017.11217
• State of the evidence 2017: an update on the connection between breast cancer and the environment Cite
  Gray JM, Rasanayagam S, Engel C, Rizzo J. State of the evidence 2017: an update on the connection between breast cancer and the environment. Environmental Health. Springer Science and Business Media LLC; 2017; 16 10.1186/s12940-017-0287-4
• Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro Cite
  Goyette S, Liang Y, Mafuvadze B, Cook M, Munir M, Hyder S. Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro. Breast Cancer: Targets and Therapy. Informa UK Limited; 2017; Volume 9:347-357 10.2147/bctt.s135371
• Mammographic Density Reduction as a Prognostic Marker for Postmenopausal Breast Cancer: Results Using a Joint Longitudinal-Survival Modeling Approach Cite
  Andersson TM-, Crowther MJ, Czene K, Hall P, Humphreys K. Mammographic Density Reduction as a Prognostic Marker for Postmenopausal Breast Cancer: Results Using a Joint Longitudinal-Survival Modeling Approach. American Journal of Epidemiology. Oxford University Press (OUP); 2017; 186:1065-1073 10.1093/aje/kwx178
• Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study Cite
  Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, et al. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2017; 186:1329-1340 10.1093/aje/kwx206
• Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk Cite
  Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Zeng D, et al. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2017; 109 10.1093/jnci/djx001
• Breast-Conserving Surgery Alone for Ductal Carcinoma In Situ: Factors Associated with Increased Risk of Local Recurrence Cite
  Mele A, Mehta P, Slanetz PJ, Brook A, Recht A, Sharma R. Breast-Conserving Surgery Alone for Ductal Carcinoma In Situ: Factors Associated with Increased Risk of Local Recurrence. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2016; 24:1221-1226 10.1245/s10434-016-5711-4
• Estrogen–progestin use and breast cancer characteristics in lean and overweight postmenopausal women Cite
  Kjartansdottir OJ, Sigurdardottir LG, Olafsdottir EJ, Jonasson JG, Ursin G, Tryggvadottir L. Estrogen–progestin use and breast cancer characteristics in lean and overweight postmenopausal women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 163:363-373 10.1007/s10549-017-4171-2
• Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program Cite
  Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. Breast Cancer Research. Springer Science and Business Media LLC; 2017; 19 10.1186/s13058-016-0798-x
• Perinatal Exposure to Bisphenol A or Diethylstilbestrol Increases the Susceptibility to Develop Mammary Gland Lesions After Estrogen Replacement Therapy in Middle-Aged Rats Cite
  Gomez AL, Delconte MB, Altamirano GA, Vigezzi L, Bosquiazzo VL, Barbisan LF, et al. Perinatal Exposure to Bisphenol A or Diethylstilbestrol Increases the Susceptibility to Develop Mammary Gland Lesions After Estrogen Replacement Therapy in Middle-Aged Rats. Hormones and Cancer. Springer Science and Business Media LLC; 2017; 8:78-89 10.1007/s12672-016-0282-1
• Population Attributable Risk of Modifiable and Nonmodifiable Breast Cancer Risk Factors in Postmenopausal Breast Cancer Cite
  Tamimi RM, Spiegelman D, Smith-Warner SA, Wang M, Pazaris M, Willett WC, et al. Population Attributable Risk of Modifiable and Nonmodifiable Breast Cancer Risk Factors in Postmenopausal Breast Cancer. American Journal of Epidemiology. Oxford University Press (OUP); 2016; 184:884-893 10.1093/aje/kww145
• Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? Cite
  Jones ME, Schoemaker MJ, Wright L, McFadden E, Griffin J, Thomas D, et al. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 115:607-615 10.1038/bjc.2016.231
• Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort Cite
  Cadeau C, Fournier A, Mesrine S, Clavel-Chapelon F, Fagherazzi G, Boutron-Ruault M. Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort. International Journal of Cancer. Wiley; 2016; 139:2193-2200 10.1002/ijc.30282
• Recreational physical activity and risk of triple negative breast cancer in the California Teachers Study Cite
  Ma H, Xu X, Clague J, Lu Y, Togawa K, Wang SS, et al. Recreational physical activity and risk of triple negative breast cancer in the California Teachers Study. Breast Cancer Research. Springer Science and Business Media LLC; 2016; 18 10.1186/s13058-016-0723-3
• Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement Cite
  Santoro N, Braunstein GD, Butts CL, Martin KA, McDermott M, Pinkerton JV. Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement. The Journal of Clinical Endocrinology & Metabolism. The Endocrine Society; 2016; 101:1318-1343 10.1210/jc.2016-1271
• Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study Cite
  Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:365-373 10.1007/s10549-016-3685-3
• Postmenopausal Female Hormone Use and Estrogen Receptor–Positive and –Negative Breast Cancer in African American Women Cite
  Rosenberg L, Bethea TN, Viscidi E, Hong C, Troester MA, Bandera EV, et al. Postmenopausal Female Hormone Use and Estrogen Receptor–Positive and –Negative Breast Cancer in African American Women. Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 108:djv361 10.1093/jnci/djv361
• Abstract A43: Population attributable risk of postmenopausal breast cancer according to known and modifiable breast cancer risk factors Cite
  Tamimi RM, Wang M, Pazzaris M, Smith-Warner SA, Willett WC, Eliassen AH, et al. Abstract A43: Population attributable risk of postmenopausal breast cancer according to known and modifiable breast cancer risk factors. Epidemiology/Lifestyle Factors. American Association for Cancer Research; 2015; 10.1158/1940-6215.prev-14-a43
• Abstract 4159: Therapeutic effects of luteolin against progestin-dependent breast cancer involves induction of apoptosis, and suppression of both stem-cell-like cells and angiogenesis Cite
  Cook MT, Liang Y, Goyette S, Mafuvadze B, Besch-Williford C, Hyder S. Abstract 4159: Therapeutic effects of luteolin against progestin-dependent breast cancer involves induction of apoptosis, and suppression of both stem-cell-like cells and angiogenesis. Tumor Biology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-4159
• Abstract 866: The proportion of breast and gynecological cancers in Australian women that can be attributed to the use of oral contraceptives and hormone replacement therapy Cite
  Jordan SJ, Wilson L, Whiteman D, Webb P. Abstract 866: The proportion of breast and gynecological cancers in Australian women that can be attributed to the use of oral contraceptives and hormone replacement therapy. Epidemiology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-866
• Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies Cite
  Pizot C, Boniol M, Mullie P, Koechlin A, Boniol M, Boyle P, et al. Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. European Journal of Cancer. Elsevier BV; 2016; 52:138-154 10.1016/j.ejca.2015.10.063
• Serum Lipids, Lipoproteins, and Risk of Breast Cancer: A Nested Case-Control Study Using Multiple Time Points Cite
  Martin LJ, Melnichouk O, Huszti E, Connelly PW, Greenberg CV, Minkin S, et al. Serum Lipids, Lipoproteins, and Risk of Breast Cancer: A Nested Case-Control Study Using Multiple Time Points. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 107:djv032-djv032 10.1093/jnci/djv032
• Lobular breast cancer: incidence and genetic and non-genetic risk factors Cite
  Dossus L, Benusiglio PR. Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Research. Springer Science and Business Media LLC; 2015; 17 10.1186/s13058-015-0546-7
• Hormone Therapy and Young-Onset Breast Cancer Cite
  O'Brien KM, Fei C, Sandler DP, Nichols HB, DeRoo LA, Weinberg CR. Hormone Therapy and Young-Onset Breast Cancer. American Journal of Epidemiology. Oxford University Press (OUP); 2015; 181:799-807 10.1093/aje/kwu347
• Mammographic breast density and breast cancer risk: interactions of percent density, absolute dense, and non-dense areas with breast cancer risk factors Cite
  Yaghjyan L, Colditz GA, Rosner B, Tamimi RM. Mammographic breast density and breast cancer risk: interactions of percent density, absolute dense, and non-dense areas with breast cancer risk factors. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 150:181-189 10.1007/s10549-015-3286-6
• Lifestyle influences on the association between pre-diagnostic hormone replacement therapy and breast cancer prognosis—Results from The Danish ‘Diet, Cancer and Health’ prospective cohort Cite
  Holm M, Olsen A, Kroman N, Tjønneland A. Lifestyle influences on the association between pre-diagnostic hormone replacement therapy and breast cancer prognosis—Results from The Danish ‘Diet, Cancer and Health’ prospective cohort. Maturitas. Elsevier BV; 2014; 79:442-448 10.1016/j.maturitas.2014.09.004
• Breast Cancer Cell Apoptosis with Phytoestrogens Is Dependent on an Estrogen-Deprived State Cite
  Obiorah IE, Fan P, Jordan VC. Breast Cancer Cell Apoptosis with Phytoestrogens Is Dependent on an Estrogen-Deprived State. Cancer Prevention Research. American Association for Cancer Research (AACR); 2014; 7:939-949 10.1158/1940-6207.capr-14-0061
• Hormonal Therapy and Risk of Breast Cancer in Mexican Women Cite
  Amadou A, Fabre A, Torres-Mejía G, Ortega-Olvera C, Angeles-Llerenas A, McKenzie F, et al. Hormonal Therapy and Risk of Breast Cancer in Mexican Women. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e79695 10.1371/journal.pone.0079695
• Effects of Dietary Apigenin on Tumor Latency, Incidence and Multiplicity in a Medroxyprogesterone Acetate- Accelerated 7,12-Dimethylbenz(a)anthracene- Induced Breast Cancer Model Cite
  Mafuvadze B, Cook M, Xu Z, Besch-Williford CL, Hyder SM. Effects of Dietary Apigenin on Tumor Latency, Incidence and Multiplicity in a Medroxyprogesterone Acetate- Accelerated 7,12-Dimethylbenz(a)anthracene- Induced Breast Cancer Model. Nutrition and Cancer. Informa UK Limited; 2013; 65:1184-1191 10.1080/01635581.2013.833637
• Hormone Replacement Therapy and Breast Cancer: Heterogeneous Risks by Race, Weight, and Breast Density Cite
  Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D. Hormone Replacement Therapy and Breast Cancer: Heterogeneous Risks by Race, Weight, and Breast Density. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:1365-1372 10.1093/jnci/djt207
• Sex Hormone Levels and Risk of Breast Cancer With Estrogen Plus Progestin Cite
  Farhat GN, Parimi N, Chlebowski RT, Manson JE, Anderson G, Huang AJ, et al. Sex Hormone Levels and Risk of Breast Cancer With Estrogen Plus Progestin. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:1496-1503 10.1093/jnci/djt243
• Risk Factors for Specific Histopathological Types of Postmenopausal Breast Cancer in the NIH-AARP Diet and Health Study Cite
  Nyante SJ, Dallal CM, Gierach GL, Park Y, Hollenbeck AR, Brinton LA. Risk Factors for Specific Histopathological Types of Postmenopausal Breast Cancer in the NIH-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2013; 178:359-371 10.1093/aje/kws471
• Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women’s Health Initiative Observational Study Cite
  Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, et al. Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women’s Health Initiative Observational Study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:526-535 10.1093/jnci/djt043
• Progesterone-Inducible Cytokeratin 5-Positive Cells in Luminal Breast Cancer Exhibit Progenitor Properties Cite
  Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, LaBarbera DV, et al. Progesterone-Inducible Cytokeratin 5-Positive Cells in Luminal Breast Cancer Exhibit Progenitor Properties. Hormones and Cancer. Springer Science and Business Media LLC; 2012; 4:36-49 10.1007/s12672-012-0127-5
• Progestin drives breast cancer growth by inducing p21CIP1 expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2 Cite
  Diaz Flaqué MC, Vicario R, Proietti CJ, Izzo F, Schillaci R, Elizalde PV. Progestin drives breast cancer growth by inducing p21CIP1 expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. Steroids. Elsevier BV; 2013; 78:559-567 10.1016/j.steroids.2012.11.003
• Menopausal symptoms and the risk of young-onset breast cancer Cite
  Fei C, DeRoo LA, Sandler DP, Weinberg CR. Menopausal symptoms and the risk of young-onset breast cancer. European Journal of Cancer. Elsevier BV; 2013; 49:798-804 10.1016/j.ejca.2012.08.030
• Hormone Therapy Use and Breast Cancer Incidence by Histological Subtypes in Sweden and Norway Cite
  Suhrke P, Maehlen J, Zahl P. Hormone Therapy Use and Breast Cancer Incidence by Histological Subtypes in Sweden and Norway. The Breast Journal. Wiley; 2012; 18:549-556 10.1111/tbj.12001
• Nandrolone and stanozolol upregulate aromatase expression and further increase IGF-I-dependent effects on MCF-7 breast cancer cell proliferation Cite
  Sirianni R, Capparelli C, Chimento A, Panza S, Catalano S, Lanzino M, et al. Nandrolone and stanozolol upregulate aromatase expression and further increase IGF-I-dependent effects on MCF-7 breast cancer cell proliferation. Molecular and Cellular Endocrinology. Elsevier BV; 2012; 363:100-110 10.1016/j.mce.2012.08.002
• Alcohol Consumption and Breast Cancer Risk Among Postmenopausal Women Following the Cessation of Hormone Therapy Use: The California Teachers Study Cite
  Horn-Ross PL, Canchola AJ, Bernstein L, Clarke CA, Lacey JV, Neuhausen SL, et al. Alcohol Consumption and Breast Cancer Risk Among Postmenopausal Women Following the Cessation of Hormone Therapy Use: The California Teachers Study. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2012; 21:2006-2013 10.1158/1055-9965.epi-12-0418
• Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study Cite
  Ritte R, Lukanova A, Berrino F, Dossus L, Tjønneland A, Olsen A, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Research. Springer Science and Business Media LLC; 2012; 14 10.1186/bcr3186
• Apigenin Induces Apoptosis and Blocks Growth of Medroxyprogesterone Acetate-Dependent BT-474 Xenograft Tumors Cite
  Mafuvadze B, Liang Y, Besch-Williford C, Zhang X, Hyder SM. Apigenin Induces Apoptosis and Blocks Growth of Medroxyprogesterone Acetate-Dependent BT-474 Xenograft Tumors. Hormones and Cancer. Springer Science and Business Media LLC; 2012; 3:160-171 10.1007/s12672-012-0114-x
• Abstract 661: Physical activity, sitting time, and postmenopausal breast cancer risk by histopathologic characteristics in a large US cohort Cite
  Patel AV, Hildebrand JS, Gaudet MM, Teras LR, Campbell PT, Gapstur SM. Abstract 661: Physical activity, sitting time, and postmenopausal breast cancer risk by histopathologic characteristics in a large US cohort. Epidemiology. American Association for Cancer Research; 2012; 10.1158/1538-7445.am2012-661
• Mammographic breast density and breast cancer risk by menopausal status, postmenopausal hormone use and a family history of breast cancer Cite
  Yaghjyan L, Colditz GA, Rosner B, Tamimi RM. Mammographic breast density and breast cancer risk by menopausal status, postmenopausal hormone use and a family history of breast cancer. Cancer Causes & Control. Springer Science and Business Media LLC; 2012; 23:785-790 10.1007/s10552-012-9936-7
• Effect of oral phytoestrogen on androgenicity and insulin sensitivity in postmenopausal women Cite
  Lee CC, Bloem CJ, Kasa-Vubu JZ, Liang L. Effect of oral phytoestrogen on androgenicity and insulin sensitivity in postmenopausal women. Diabetes, Obesity and Metabolism. Wiley; 2011; 14:315-319 10.1111/j.1463-1326.2011.01532.x
• Hops (Humulus lupulus) Inhibits Oxidative Estrogen Metabolism and Estrogen-Induced Malignant Transformation in Human Mammary Epithelial cells (MCF-10A) Cite
  Hemachandra LP, Madhubhani P, Chandrasena R, Esala P, Chen S, Main M, et al. Hops (Humulus lupulus) Inhibits Oxidative Estrogen Metabolism and Estrogen-Induced Malignant Transformation in Human Mammary Epithelial cells (MCF-10A). Cancer Prevention Research. American Association for Cancer Research (AACR); 2011; 5:73-81 10.1158/1940-6207.capr-11-0348
• Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms Cite
  Geller SE, Shulman LP, van Breemen RB, Banuvar S, Zhou Y, Epstein G, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms. Menopause. Ovid Technologies (Wolters Kluwer Health); 2009; 16:1156-1166 10.1097/gme.0b013e3181ace49b
• Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials Cite
  Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson G, et al. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 132:275-285 10.1007/s10549-011-1848-9
• Soy Isoflavones in the Prevention of Menopausal Bone Loss and Menopausal Symptoms Cite
  Levis S. Soy Isoflavones in the Prevention of Menopausal Bone Loss and Menopausal Symptoms. Archives of Internal Medicine. American Medical Association (AMA); 2011; 171:1363 10.1001/archinternmed.2011.330
• Association of Hormone-Related Characteristics and Breast Cancer Risk by Estrogen Receptor/Progesterone Receptor Status in the Shanghai Breast Cancer Study Cite
  Bao P, Shu XO, Gao Y, Zheng Y, Cai H, Deming SL, et al. Association of Hormone-Related Characteristics and Breast Cancer Risk by Estrogen Receptor/Progesterone Receptor Status in the Shanghai Breast Cancer Study. American Journal of Epidemiology. Oxford University Press (OUP); 2011; 174:661-671 10.1093/aje/kwr145
• Apigenin Prevents Development of Medroxyprogesterone Acetate-Accelerated 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Sprague–Dawley Rats Cite
  Mafuvadze B, Benakanakere I, López Pérez FR, Besch-Williford C, Ellersieck MR, Hyder SM. Apigenin Prevents Development of Medroxyprogesterone Acetate-Accelerated 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Sprague–Dawley Rats. Cancer Prevention Research. American Association for Cancer Research (AACR); 2011; 4:1316-1324 10.1158/1940-6207.capr-10-0382
• Relationship between Menopausal Symptoms and Risk of Postmenopausal Breast Cancer Cite
  Huang Y, Malone KE, Cushing-Haugen KL, Daling JR, Li CI. Relationship between Menopausal Symptoms and Risk of Postmenopausal Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2011; 20:379-388 10.1158/1055-9965.epi-10-0998
• Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors Cite
  Barnes BB, Steindorf K, Hein R, Flesch-Janys D, Chang-Claude J. Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors. Cancer Epidemiology. Elsevier BV; 2011; 35:345-352 10.1016/j.canep.2010.11.003
• Abstract B99: Hot flashes, hormone therapy, and breast cancer risk: The Women's Health Initiative Clinical Trials Cite
  Farhat GN, LaCroix A, Grady D, Chlebowski R, Vitolins M, Manson J, et al. Abstract B99: Hot flashes, hormone therapy, and breast cancer risk: The Women's Health Initiative Clinical Trials. Epidemiology and Lifestyle Factors. American Association for Cancer Research; 2010; 10.1158/1940-6207.prev-10-b99
• A cluster of inflammatory breast cancer (IBC) in an office setting: Additional evidence of the importance of environmental factors in IBC etiology Cite
  Levine . A cluster of inflammatory breast cancer (IBC) in an office setting: Additional evidence of the importance of environmental factors in IBC etiology. Oncology Reports. Spandidos Publications; 2010; 24 10.3892/or_00000983
• Breast Cancer Incidence and Hormone Replacement Therapy in Canada Cite
  De P, Neutel CI, Olivotto I, Morrison H. Breast Cancer Incidence and Hormone Replacement Therapy in Canada. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:1489-1495 10.1093/jnci/djq345
• Modifiable risk factors and survival in women diagnosed with primary breast cancer: results from a prospective cohort study Cite
  Hellmann SS, Thygesen LC, Tolstrup JS, Grønbæk M. Modifiable risk factors and survival in women diagnosed with primary breast cancer: results from a prospective cohort study. European Journal of Cancer Prevention. Ovid Technologies (Wolters Kluwer Health); 2010; 19:366-373 10.1097/cej.0b013e32833b4828
• Breast Cancer Risk by Breast Density, Menopause, and Postmenopausal Hormone Therapy Use Cite
  Kerlikowske K, Cook AJ, Buist DS, Cummings SR, Vachon C, Vacek P, et al. Breast Cancer Risk by Breast Density, Menopause, and Postmenopausal Hormone Therapy Use. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:3830-3837 10.1200/jco.2009.26.4770
• Risk Factors for Ductal, Lobular, and Mixed Ductal-Lobular Breast Cancer in a Screening Population Cite
  Phipps AI, Li CI, Kerlikowske K, Barlow WE, Buist DSM. Risk Factors for Ductal, Lobular, and Mixed Ductal-Lobular Breast Cancer in a Screening Population. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:1643-1654 10.1158/1055-9965.epi-10-0188
• Breast cancer patients with lobular cancer more commonly have a father than a mother diagnosed with cancer Cite
  Ellberg C, Olsson H. Breast cancer patients with lobular cancer more commonly have a father than a mother diagnosed with cancer. BMC Cancer. Springer Science and Business Media LLC; 2011; 11 10.1186/1471-2407-11-497
• Abstract 5741: Change in mammographic density with estrogen and progestin therapy: A measure of breast cancer risk in the Women's Health Initiative Cite
  Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Heiss G, et al. Abstract 5741: Change in mammographic density with estrogen and progestin therapy: A measure of breast cancer risk in the Women's Health Initiative. Epidemiology. American Association for Cancer Research; 2010; 10.1158/1538-7445.am10-5741
• Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition Cite
  Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, et al. Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer. Wiley; 2010; 128:144-156 10.1002/ijc.25314
• Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk Cite
  Shantakumar S, Terry MB, Paykin A, Teitelbaum SL, Britton JA, Moorman PG, et al. Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk. American Journal of Epidemiology. Oxford University Press (OUP); 2007; 165:1187-1198 10.1093/aje/kwm006
• New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk Cite
  Crandall CJ. New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk. Archives of Internal Medicine. American Medical Association (AMA); 2009; 169:1684 10.1001/archinternmed.2009.303
• Dietary β-carotene, vitamin C and E intake and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Cite
  Nagel G, Linseisen J, van Gils CH, Peeters PH, Boutron-Ruault MC, Clavel-Chapelon F, et al. Dietary β-carotene, vitamin C and E intake and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 119:753-765 10.1007/s10549-009-0444-8
• Curcumin delays development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors Cite
  Carroll CE, Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM. Curcumin delays development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors. Menopause. Ovid Technologies (Wolters Kluwer Health); 2010; 17:178-184 10.1097/gme.0b013e3181afcce5
• The Use of Herbal Preparations to Alleviate Climacteric Disorders and Risk of Postmenopausal Breast Cancer in a German Case-Control Study Cite
  Obi N, Chang-Claude J, Berger J, Braendle W, Slanger T, Schmidt M, et al. The Use of Herbal Preparations to Alleviate Climacteric Disorders and Risk of Postmenopausal Breast Cancer in a German Case-Control Study. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:2207-2213 10.1158/1055-9965.epi-09-0298
• The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004 Cite
  Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC. The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:1763-1769 10.1158/1055-9965.epi-08-1082
• Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort Study Cite
  Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort Study. American Journal of Epidemiology. Oxford University Press (OUP); 2009; 169:1251-1259 10.1093/aje/kwp036
• Meat Intake and Mortality Cite
  Sinha R, Cross AJ, Graubard BI, Leitzmann MF, Schatzkin A. Meat Intake and Mortality. Archives of Internal Medicine. American Medical Association (AMA); 2009; 169:562 10.1001/archinternmed.2009.6
• Interactions between intakes of alcohol and postmenopausal hormones on risk of breast cancer Cite
  Nielsen NR, Grønbaek M. Interactions between intakes of alcohol and postmenopausal hormones on risk of breast cancer. International Journal of Cancer. Wiley; 2007; 122:1109-1113 10.1002/ijc.23195
• No Difference Between Red Wine or White Wine Consumption and Breast Cancer Risk Cite
  Newcomb PA, Nichols HB, Beasley JM, Egan K, Titus-Ernstoff L, Hampton JM, et al. No Difference Between Red Wine or White Wine Consumption and Breast Cancer Risk. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:1007-1010 10.1158/1055-9965.epi-08-0801